Zoetis (ZTS): Harnessing Growth with Minimum Rivalry
Fundsmith, an investment management firm based in London, has released its annual 2025 investor letter for its “Fundsmith Equity Fund.” A copy of the letter can be downloaded here.
Zoetis Inc. (ZTS)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Zevenbergen Capital Investments Nancy Zevenbergen | 14,545 | $1,830,052 | -12% | 0.04% |
| 2. | Bourgeon Capital John Zaro | 1,869 | $235,158 | +1% | 0.04% |
| 3. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $165.48 | 2,100 | $347,508.00 | 7,590 | 2021-02-19 | Filing | |
| $164.89 | 2,900 | $478,181.00 | 5,490 | 2021-02-19 | Filing | |
| $163.80 | 2,590 | $424,242.00 | 2,590 | 2021-02-19 | Filing | |
| $74.56 | 10 | $745.60 | 17 | 2018-01-11 | Filing | |
| $50.31 | 7 | $352.17 | 7 | 2016-10-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $170.00 | 652 | $110,840.00 | 15,129 | 2025-06-03 | Filing | |
| $170.00 | 326 | $55,420.00 | 15,781 | 2025-03-10 | Filing | |
| $166.14 | 1,210 | $201,029.40 | 11,245 | 2025-03-11 | Filing | |
| $156.68 | 382 | $59,852.26 | 94,194 | 2025-02-19 | Filing | |
| $171.18 | 326 | $55,804.68 | 16,107 | 2025-02-11 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 4,932,787 | $622,221,753 | 0.53% | |
| 2. | 2,378,772 | $299,297,093 | 1.75% | |
| 3. | 1,631,619 | $205,290,303 | 0.28% | |
| 4. | 1,188,371 | $149,520,839 | 0.23% | |
| 5. | 1,070,558 | $134,697,617 | 1.4% |
News See All
BofA Downgrades Zoetis (ZTS) to Neutral, Cuts Price Target
In other news, on December 5, Zoetis Inc. (NYSE:ZTS) announced that Health Canada approved Portela™ (relfovetmab injection) for the relief of pain linked to osteoarthritis, or OA, in cats.
14 Best Pharma Dividend Stocks to Buy in 2026
For most drugmakers, the US is the largest single market. Prices there are often close to three times higher than in other developed countries. Branded medicines carry even steeper premiums.
Zoetis (ZTS) Positioned Within Morgan Stanley’s 2026 Healthcare Playbook
On December 18, Morgan Stanley lowered its price target on Zoetis Inc. (NYSE:ZTS) to $160 from $175 and kept an Overweight rating.
15 Dividend Stocks With Low Payout Ratios and Strong Upside
The payout ratio is one of the simplest ways to assess whether a dividend can sustain itself over time. It shows how much of a company’s earnings are being paid out to shareholders.
HSBC Cuts Zoetis Inc. (ZTS)'s Price Target To $140 From $180, Keeps Buy Rating
Zoetis Inc. (NYSE:ZTS) is among the 11 Most Oversold S&P 500 Stocks Heading into 2026.
11 Most Oversold S&P 500 Stocks Heading into 2026
During an interview with CNBC on November 12, Tom Sosnoff, founder and CEO of the financial platform LossDog, advised retail investors to focus on buying oversold and cheap stocks rather than chasing ...
11 Good Stocks to Buy According to Analysts
Earlier, on November 17, Morgan Stanley raised its S&P 500 2026 year-end target to 7,800. The decision is reportedly driven by robust earnings growth and AI-enhanced gains in efficiency.
Zoetis Inc. (ZTS): A Bull Case Theory
We came across a bullish thesis on Zoetis Inc. on Value investing subreddit by anonymous_sheep1. In this article, we will summarize the bulls’ thesis on ZTS.
Stifel Lowers Zoetis (ZTS) PT to $130, Maintains 'Hold' Due to Aggressive 2026 Revenue Outlook
Zoetis Inc. (NYSE:ZTS) is one of the most profitable large cap stocks to buy right now.
Hedge Fund Resource Center Billionaire Hedge Funds
